Physician profile
Dylan Peter Elman
NPI 1154715050
$994.63
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $560 · 2024: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $137.42 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.95 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $114.73 | 2021-2022 | |
| Inspire Medical Systems, INC. | $105.57 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $103.27 | 2021-2022 | |
| Abbvie INC. | $102.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $75.20 | 2021-2022 | |
| Pfizer INC. | $51.45 | 2022 | |
| Amgen INC. | $47.62 | 2022 | |
| Lilly USA, LLC | $26.49 | 2021-2022 | |
| Astellas Pharma US INC | $24.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.20 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.64 | 2022 | |
| Celgene Corporation | $15.31 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Elman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.